InvestmentUpdated on 27 March 2025
Invest in the Future of CRISPR Diagnostics
About
Scope Biosciences has developed a modular CRISPR-Cas platform delivering rapid, SNP-specific diagnostics without the need for complex hardware. Already generating revenue in agriculture, we are now expanding into medical diagnostics with support from a 2.5M EIC Transition grant. We are progressing toward ISO13485 certification and clinical validation, with multiple product and partnership opportunities on the horizon. We’re seeking investors to join us at this critical growth phase
Stage
- Growth and Establishment
- Speed and Development
- Startup
Applies to
- Agriculture & Food
- Health Biotechnology
Organisation
Similar opportunities
Partnership
Partner with Scope Biosciences on CRISPR-based Diagnostic Co-Development
- Development
Niek Savelkoul
CEO at Scope Biosciences B.V.
Wageningen, Netherlands
Investment
- Energy
- Expansion
- AI, Data & ICT
- Speed and Development
- Growth and Establishment
- Climate & Environmental Tech
- Quantum, Advanced Computing & Semiconductors
Lovisa Urheim
Head of Strategic Initiatives at Plexigrid
Stockholm, Sweden
Investment
- Mobility
- Speed and Development
- Climate & Environmental Tech
- Advanced Manufacturing & Advanced Materials
Antoine Toulemont
European Affairs Adviser at Aura Aero
Brussels, Belgium